Skip to main content

Table 4 Multivariate analysis of prognostic factors

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

VariableHR95% CIp value
GPS = 00.470.29–0.76< 0.002
CEA ≤ 10 ng/mL0.470.29–0.78< 0.003
  1. CEA carcinoembryonic antigen, CI confidence interval, HR hazard ratio, GPS Glasgow prognostic score